Breast Cancer Clinical Trials in Nanchang
6 recruitingNanchang, China
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting
Phase 3
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Breast Cancer
Daiichi Sankyo250 enrolled86 locationsNCT05950945
Recruiting
Phase 3
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Breast Cancer
AstraZeneca300 enrolled82 locationsNCT06635447
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Breast CancerHER2-low Breast CancerHER2-positive Breast Cancer+1 more
Daiichi Sankyo800 enrolled54 locationsNCT06210776
Recruiting
Phase 3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd400 enrolled87 locationsNCT06079983
Recruiting
Phase 3
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University688 enrolled17 locationsNCT02062489